ATAI Life Sciences N.V. (ATAI) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
WALLSTRASSE 16 BERLIN, 10179 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 190,613 | 362,266 | |||
| Cash and cash equivalents | 190,613 | 362,266 | |||
| Receivables | 913 | ||||
| Prepaid expense | 7,665 | 7,713 | |||
| Other current assets | 1,745 | 756 | |||
| Other undisclosed current assets | 87,122 | 3,434 | |||
| Total current assets: | 287,145 | 375,082 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | |||||
| Property, plant and equipment | 928 | 149 | |||
| Long-term investments and receivables | 14,017 | 31,594 | |||
| Due from related parties | 7,262 | 3,835 | |||
| Long-term investments | 6,755 | 27,759 | |||
| Other noncurrent assets | 3,351 | 7,341 | |||
| Total noncurrent assets: | 18,296 | 39,084 | |||
| TOTAL ASSETS: | 305,441 | 414,166 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 19,705 | 20,833 | |||
| Accounts payable | 2,399 | 6,004 | |||
| Accrued liabilities | 17,306 | 14,829 | |||
| Debt | 82,500 | ||||
| Business combination, contingent consideration, liability | 51 | ||||
| Other liabilities | 192 | 51 | |||
| Other undisclosed current liabilities | (82,500) | ||||
| Total current liabilities: | 19,897 | 20,935 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 743 | ||||
| Long-term debt, excluding current maturities | 743 | ||||
| Liabilities, other than long-term debt | 4,761 | 6,529 | |||
| Other liabilities | 3,708 | 4,097 | |||
| Operating lease, liability | 100 | ||||
| Business combination, contingent consideration, liability | 953 | 2,432 | |||
| Other undisclosed noncurrent liabilities | 15,017 | ||||
| Total noncurrent liabilities: | 19,778 | 7,272 | |||
| Total liabilities: | 39,675 | 28,207 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 260,740 | 376,908 | |||
| Common stock | 18,562 | 18,002 | |||
| Additional paid in capital | 774,092 | 725,045 | |||
| Accumulated other comprehensive loss | (21,702) | (8,336) | |||
| Accumulated deficit | (510,188) | (357,803) | |||
| Other undisclosed equity, attributable to parent | (24) | ||||
| Equity, attributable to noncontrolling interest | 5,026 | 9,051 | |||
| Total equity: | 265,766 | 385,959 | |||
| TOTAL LIABILITIES AND EQUITY: | 305,441 | 414,166 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Revenues | 233 | 20,376 | ||
| Gross profit: | 233 | 20,376 | ||
| Operating expenses | (145,020) | (156,181) | ||
| Operating loss: | (144,787) | (135,805) | ||
| Nonoperating income (expense) | 9,605 | (796) | ||
| Investment income, nonoperating | 548 | 205 | ||
| Gain, foreign currency transaction, before tax | 6,902 | 8,481 | ||
| Other nonoperating expense | (1,412) | (293) | ||
| Interest and debt expense | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||
| Loss from continuing operations before equity method investments, income taxes: | (135,182) | (136,601) | ||
| Loss from equity method investments | (16,006) | (58,555) | ||
| Other undisclosed income from continuing operations before income taxes | 16,006 | 58,555 | ||
| Loss from continuing operations before income taxes: | (135,182) | (136,601) | ||
| Income tax expense (benefit) | (6,229) | 3,989 | ||
| Loss from continuing operations: | (141,411) | (132,612) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (132,612) | ||
| Other undisclosed net loss | (16,006) | (41,632) | ||
| Net loss: | (157,417) | (174,244) | ||
| Net income attributable to noncontrolling interest | 5,032 | 6,436 | ||
| Net loss available to common stockholders, diluted: | (152,385) | (167,808) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Net loss: | (157,417) | (174,244) | ||
| Other undisclosed comprehensive loss | (13,366) | (14,155) | ||
| Comprehensive loss: | (170,783) | (188,399) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 4,982 | 6,460 | ||
| Comprehensive loss, net of tax, attributable to parent: | (165,801) | (181,939) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.